Company Long-Term Loans and Borrowings: Hutchison MediPharma (HCM)

Costs for temperature-controlled air freight of drugs impact the long-term liabilities trend for HUTCHMED (China) Limited (HCM), as shown on the GURU.Markets portal, where the value of 0.08 corresponds to the current metric. The company's own high-tech plants in China ensure process stability, while experienced management supports a confident course toward portfolio globalization by successfully overcoming international regulatory barriers.

HCM hutch-med.com: Company Long-Term Debt in the range 07/04/2022 - 10/31/2026

Summary analytical data breakdowns for HUTCHMED Ltd (HCM)

- market value and analyst target forecast:

Market Price hutch-med.com|HCM - Price Target Chart

- company stock exchange capitalization indicators:

Market Value HUTCHMED|HCM - Enterprise Value

- book capitalization information:

Book Value per Share HUTCHMED|HCM - Company Book Value|Market Value to Book Value Ratio hutch-med.com|HCM - Cumulative Company Assets

- business debt structure and liquidity details:

- business earnings and investment ratios data:

HCM - Company Net Income

Analysis of all company metrics:hutch-med.com - HCM

This indicator aggregates all long-term credit obligations and loans, allowing GURU.Markets to track financial pressure dynamics and credit risks prior to the release of official financial statements. For HUTCHMED (China) Limited (HCM), which is pursuing global expansion through licensing partnerships without M&A, the company's long-term loans and borrowings reflect the cost of scaling R&D, where rising debt may signal the business's critical sensitivity to interest rate fluctuations.

Who HUTCHMED (China) Limited competes with

incyte.com (INCY) - Long-Term Debt|NUVB - Company Long-Term Debt|Company Long-Term Loans and Borrowings DAWN (Day One Biopharmaceuticals, Inc.)|MNPR: Company Long-Term Debts|Inhibrx Corp (INBX) - Company Long-Term Debts|Company Long-Term Debt I-Mab Biopharma Co., Ltd.|Company Long-Term Debt FENC|Company Long-Term Liabilities HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma Inc.) - Company Long-Term Loans and Borrowings|Company Long-Term Debt coherus.com CHRS|Corbus Pharmaceuticals, Inc. (CRBP) - Long-Term Debt|CRDF - Company Long-Term Debt|BYSI (beyondspringpharma.com) - Company Long-Term Indebtedness|BCAB: Company Long-Term Debts|Company Long-Term Liabilities Lixte Biotechnology Holdings Inc.|Company Long-Term Debt Citius Pharmaceuticals Inc.|Long-Term Debt Cellectar Corp CLRB|Company Long-Term Debt BioLineRx Ltd. (BLRX)|Company Long-Term Debt CANF (canfite.com)|Company Long-Term Debt Aprea Therapeutics, Inc. APRE|Kazia Therapeutics Ltd (KZIA) - Long-Term Debt|Silexion - Company Long-Term Debts|Long-Term Indebtedness NuCana plc (NCNA)|CMRX (Chimerix, Inc.) - Company Long-Term Liabilities|Long-Term Debt cyclacel.com (CYCC)|Company Long-Term Liabilities GTHX|KRON: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities KTRA (Kintara)|Amount of Long-Term Liabilities ONCT|Company Long-Term Debts PRTG (Portage Biotech Inc.)